A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients with Advanced or Metastatic Solid Tumor Malignancies

Cancer type: Solide tumores

Phase: I

Principal Investigator: Mau-Sørensen Morten

Country: DK

Keywords: Denmark, Rigshospitalet, selective inhibitor of nuclear expert, CRM-1, solid tumors

Status: Inclusion completed

Link to